Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: Zai Lab Limited, 3 years.
Zai Lab Limited
Director
Dianthus Therapeutics Inc.
Director
Zenas BioPharma Inc.
Director · See Remarks
Chief executive roles
Zenas BioPharma Inc.
· Chief Executive Officer
Since September 2024
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 17, 2026 | Zai Lab Limited | Grant or award | +22,371 | — | — |
| May 18, 2026 | Zenas BioPharma Inc. | Open-market purchase | +60,000 | $16.88 | $1,012,800 |
| Apr 29, 2026 | Zenas BioPharma Inc. | Open-market purchase | +35,000 | $17.62 | $616,700 |
| Apr 28, 2026 | Zenas BioPharma Inc. | Open-market purchase | +25,000 | $18.02 | $450,500 |
| Mar 31, 2026 | Zenas BioPharma Inc. | Open-market purchase | +34,000 | $19.31 | $656,540 |
| Mar 30, 2026 | Zenas BioPharma Inc. | Open-market purchase | +20,000 | $18.23 | $364,600 |
| Feb 2, 2026 | Zenas BioPharma Inc. | Open-market purchase | +57,000 | $17.96 | $1,023,720 |
| Jan 9, 2026 | Zenas BioPharma Inc. | Open-market purchase | +20,000 | $16.55 | $331,000 |
| Jan 8, 2026 | Zenas BioPharma Inc. | Open-market purchase | +30,000 | $16.30 | $489,000 |
| Jan 7, 2026 | Zenas BioPharma Inc. | Open-market purchase | +50,000 | $16.38 | $819,000 |
| Oct 7, 2025 | Zenas BioPharma Inc. | Open-market purchase | +36,928 | $20.85 | $769,949 |
| Jun 18, 2025 | Zai Lab Limited | Grant or award | +10,831 | — | — |
| Feb 18, 2025 | Zenas BioPharma Inc. | Open-market purchase | +25,000 | $6.67 | $166,750 |
| Dec 4, 2024 | Zenas BioPharma Inc. | Open-market purchase | +45,000 | $9.98 | $449,100 |
| Dec 3, 2024 | Zenas BioPharma Inc. | Open-market purchase | +25,000 | $10.76 | $269,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.